SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

NCT06222580 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With FLT3/ITD Mutation
Acute Myeloid Leukemia With KMT2A Rearrangement
Acute Myeloid Leukemia With NPM1 Mutation
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration and Biopsy
DRUG: Gilteritinib
DRUG: Revumenib
PROCEDURE: Echocardiography Test
PROCEDURE: Multigated Acquisition Scan

Sponsor

Uma Borate